{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:54Z","timestamp":1789475574934,"version":"build-2803163510"},"reference-count":145,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016925","name":"Takeda Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162393"],"award-info":[{"award-number":["PJT-162393"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is a major cause of morbidity and mortality among people with inflammatory bowel disease (IBD). Intestinal cancers may arise as a complication of IBD itself, while extra-intestinal cancers may arise due to some of the immunosuppressive therapies used to treat IBD. Colorectal cancer (CRC) and small bowel cancer risks remain elevated among persons with IBD as compared to age-and sex-matched members of the general population, and the lifetime risk of these cancers is strongly correlated to cumulative intestinal inflammatory burden. However, the cumulative risk of cancer, even among those with IBD is still low. Some studies suggest that IBD-CRC incidence has declined over the years, possibly owing to improved treatment standards and improved detection and management of early neoplastic lesions. Across studies of extra-intestinal cancers, there are generally higher incidences of melanoma, hepatobiliary cancer, and lung cancer and no higher incidences of breast cancer or prostate cancer, with equivocal risk of cervical cancer, among persons with IBD. While the relative risks of some extra-intestinal cancers are increased with treatment, the absolute risks of these cancers remain low and the decision to forego treatment in light of these risks should be carefully weighed against the increased risks of intestinal cancers and other disease-related complications with undertreated inflammatory disease. Quality improvement efforts should focus on optimized surveillance of cancers for which surveillance strategies exist (colorectal cancer, hepatobiliary cancer, cervical cancers, and skin cancers) and the development of cost-effective surveillance strategies for less common cancers associated with IBD.<\/jats:p>","DOI":"10.1093\/jcag\/gwad006","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T10:38:26Z","timestamp":1678358306000},"page":"S83-S96","source":"Crossref","is-referenced-by-count":18,"title":["The 2023 Impact of Inflammatory Bowel Disease in Canada: Cancer and IBD"],"prefix":"10.1093","volume":"6","author":[{"given":"Sanjay K","family":"Murthy","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario , Canada"},{"name":"The Ottawa Hospital IBD Centre , Ottawa, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-8426","authenticated-orcid":false,"given":"M Ellen","family":"Kuenzig","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W","family":"Windsor","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Matthews","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0021-2161","authenticated-orcid":false,"given":"Parul","family":"Tandon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3598","authenticated-orcid":false,"given":"Eric I","family":"Benchimol","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"ICES , Toronto, Ontario , Canada"},{"name":"Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario , Canada"},{"name":"Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8041-3574","authenticated-orcid":false,"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"IBD Clinical and Research Centre, University of Manitoba , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University , Montr\u00e9al, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0675-7226","authenticated-orcid":false,"given":"Stephanie","family":"Coward","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Jones","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Clinical Health, and Epidemiology, Dalhousie University , Halifax, Nova Scotia , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Lee","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura E","family":"Targownik","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-525X","authenticated-orcid":false,"given":"Juan-Nicol\u00e1s","family":"Pe\u00f1a-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Community Health and Epidemiology, University of Saskatchewan , Saskatoon, Saskatchewan , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-027X","authenticated-orcid":false,"given":"Noelle","family":"Rohatinsky","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Saskatchewan , Saskatoon, Saskatchewan , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ghandeharian","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saketh","family":"Meka","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S","family":"Chis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, The Royal Children\u2019s Hospital Melbourne , Parkville , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Davis","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Weinstein","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H B","family":"Im","sequence":"additional","affiliation":[{"name":"SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children , Toronto, Ontario , Canada"},{"name":"Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Goddard","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gorospe","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Loschiavo","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"McQuaid","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"D\u2019Addario","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Silver","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Oppenheim","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Canada , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-2356","authenticated-orcid":false,"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"IBD Clinical and Research Centre, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg, Manitoba , Canada"},{"name":"CancerCare Manitoba Research Institute , Winnipeg, Manitoba , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"9","key":"2023090515134187100_CIT0001","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/gutjnl-2014-307983","article-title":"Predictors and risks for death in a population-based study of persons with IBD in Manitoba","volume":"64","author":"Bernstein","year":"2015","journal-title":"Gut"},{"key":"2023090515134187100_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.18.s2.2.x","article-title":"Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease","volume":"18","author":"Munkholm","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"2023090515134187100_CIT0003","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"9317","key":"2023090515134187100_CIT0004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"2023090515134187100_CIT0005","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"2023090515134187100_CIT0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"2023090515134187100_CIT0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"9","key":"2023090515134187100_CIT0008","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2023090515134187100_CIT0009","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090515134187100_CIT0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"2023090515134187100_CIT0011","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"2023090515134187100_CIT0012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0013","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn\u2019s disease: Results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515134187100_CIT0014","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090515134187100_CIT0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0016","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2023090515134187100_CIT0017","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2023090515134187100_CIT0018","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2023090515134187100_CIT0019","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"key":"2023090515134187100_CIT0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(23)01469-5","article-title":"Temporal trends and relative risks of intestinal and extra-intestinal cancers in persons with inflammatory bowel diseases: A population-based study from a large Canadian province (Abstract)","author":"Murthy","year":"2023","journal-title":"Gastroenterology"},{"key":"2023090515134187100_CIT0021","article-title":"Cancers associated with inflammatory bowel disease in Canada: A population-based analysis of cases and their matched controls (Abstract)","author":"Coward","year":"2023","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515134187100_CIT0022","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S0016-5085(16)30833-2","article-title":"1124 there is no decrease in the mortality from IBD associated colorectal cancers over 25 years: A population based analysis","volume":"150","author":"Singh","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090515134187100_CIT0023","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.gastro.2012.04.054","article-title":"Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010","volume":"143","author":"Herrinton","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"2023090515134187100_CIT0024","doi-asserted-by":"crossref","first-page":"e220595","DOI":"10.1001\/jamanetworkopen.2022.0595","article-title":"Development of cancer among patients with pediatric-onset inflammatory bowel disease: A meta-analysis of population-based studies","volume":"5","author":"Elmahdi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2023090515134187100_CIT0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: A systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090515134187100_CIT0026","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"2023090515134187100_CIT0027","article-title":"Risks of melanoma and nonmelanoma skin cancers pre- and post-inflammatory bowel disease diagnosis","author":"Narous","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2023090515134187100_CIT0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090515134187100_CIT0029","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cgh.2013.03.034","article-title":"Risk of cancer in patients with inflammatory bowel diseases: A nationwide population-based cohort study with 30 years of follow-up evaluation","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023090515134187100_CIT0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023090515134187100_CIT0031","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: A population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023090515134187100_CIT0032","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: A population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"issue":"7","key":"2023090515134187100_CIT0033","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: Meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2023090515134187100_CIT0034","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2023090515134187100_CIT0035","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0016-5085(92)91185-7","article-title":"DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis","volume":"103","author":"Rubin","year":"1992","journal-title":"Gastroenterology"},{"issue":"4 Pt 1","key":"2023090515134187100_CIT0036","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0016-5085(92)90751-J","article-title":"DNA aneuploidy in ulcerative colitis: Reproducibility, topographic distribution, and relation to dysplasia","volume":"102","author":"Lofberg","year":"1992","journal-title":"Gastroenterology"},{"issue":"6","key":"2023090515134187100_CIT0037","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S0016-5085(98)70037-X","article-title":"Multifocal neoplasia involving the colon and appendix in ulcerative colitis: Pathological and molecular features","volume":"115","author":"Lyda","year":"1998","journal-title":"Gastroenterology"},{"issue":"6","key":"2023090515134187100_CIT0038","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/hupa.2000.7643","article-title":"Microsatellite instability and K-ras mutations in patients with ulcerative colitis","volume":"31","author":"Lyda","year":"2000","journal-title":"Hum Pathol"},{"issue":"1 Pt 1","key":"2023090515134187100_CIT0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0016-5085(82)80281-3","article-title":"Mortality in ulcerative colitis","volume":"83","author":"Gyde","year":"1982","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0040","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/j.gastro.2009.01.064","article-title":"Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease","volume":"136","author":"Soderlund","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090515134187100_CIT0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ajg.2010.428","article-title":"The risk of inflammatory bowel disease-related colorectal carcinoma is limited: Results from a nationwide nested case-control study","volume":"106","author":"Baars","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2023090515134187100_CIT0042","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","article-title":"Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years","volume":"143","author":"Jess","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515134187100_CIT0043","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2005.12.035","article-title":"Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis","volume":"130","author":"Rutter","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515134187100_CIT0044","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: A meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"issue":"18","key":"2023090515134187100_CIT0045","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. A population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"2023090515134187100_CIT0046","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"2023090515134187100_CIT0047","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1053\/j.gastro.2006.03.028","article-title":"Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study","volume":"130","author":"Velayos","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"2023090515134187100_CIT0048","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.cgh.2013.06.023","article-title":"Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: A case-control study","volume":"11","author":"Rubin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023090515134187100_CIT0049","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1053\/j.gastro.2007.08.001","article-title":"Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study","volume":"133","author":"Gupta","year":"2007","journal-title":"Gastroenterology"},{"issue":"12","key":"2023090515134187100_CIT0050","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/gut.2003.038505","article-title":"Cancer surveillance in longstanding ulcerative colitis: Endoscopic appearances help predict cancer risk","volume":"53","author":"Rutter","year":"2004","journal-title":"Gut"},{"issue":"3","key":"2023090515134187100_CIT0051","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/gutjnl-2017-314190","article-title":"Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: A large single-centre study","volume":"68","author":"Choi","year":"2019","journal-title":"Gut"},{"issue":"2","key":"2023090515134187100_CIT0052","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ibd\/izaa047","article-title":"Cumulative histologic inflammation predicts colorectal neoplasia in ulcerative colitis: A validation study","volume":"27","author":"Yvellez","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2023090515134187100_CIT0053","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cgh.2016.11.025","article-title":"Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: A systematic review and meta-analysis","volume":"15","author":"Fumery","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023090515134187100_CIT0054","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.gastro.2008.12.007","article-title":"A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy","volume":"136","author":"Martinez","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"2023090515134187100_CIT0055","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1053\/gast.2001.24052","article-title":"Family history as a risk factor for colorectal cancer in inflammatory bowel disease","volume":"120","author":"Askling","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0056","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0016-5085(98)70077-0","article-title":"Familial predisposition for colorectal cancer in chronic ulcerative colitis: A case-control study","volume":"115","author":"Nuako","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"2023090515134187100_CIT0057","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mge.2002.125367","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis","volume":"56","author":"Soetikno","year":"2002","journal-title":"Gastrointest Endosc"},{"issue":"4","key":"2023090515134187100_CIT0058","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/gutjnl-2017-315440","article-title":"Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: Results of a 15-year multicentre, multinational cohort study","volume":"68","author":"Ten Hove","year":"2019","journal-title":"Gut"},{"issue":"4","key":"2023090515134187100_CIT0059","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: A population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"2023090515134187100_CIT0060","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S0016-5085(16)30833-2","article-title":"There is no decrease in the mortality from IBD associated colorectal cancers over 25 years: A population based analysis","volume":"150","author":"Singh","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090515134187100_CIT0061","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/MIB.0b013e3182802af7","article-title":"Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn\u2019s disease: A nationwide population-based cohort study","volume":"19","author":"Ording","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2023090515134187100_CIT0062","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ibd.21365","article-title":"Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: A nationwide Japanese study","volume":"17","author":"Watanabe","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2023090515134187100_CIT0063","doi-asserted-by":"crossref","first-page":"e0272158","DOI":"10.1371\/journal.pone.0272158","article-title":"Characteristics of colorectal cancer and use of colonoscopy before colorectal cancer diagnosis among individuals with inflammatory bowel disease: A population-based study","volume":"17","author":"Hansen","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"2023090515134187100_CIT0064","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11605-010-1402-9","article-title":"Intestinal cancer risk in Crohn\u2019s disease: A meta-analysis","volume":"15","author":"Laukoetter","year":"2011","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"2023090515134187100_CIT0065","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2036.2006.02854.x","article-title":"Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn\u2019s disease","volume":"23","author":"Canavan","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2023090515134187100_CIT0066","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/php.13513","article-title":"Intramolecular charge transfer in the azathioprine prodrug quenches intersystem crossing to the reactive triplet state in 6-mercaptopurine","volume":"98","author":"Ortiz-Rodr\u00edguez","year":"2022","journal-title":"Photochem Photobiol"},{"issue":"15","key":"2023090515134187100_CIT0067","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2023090515134187100_CIT0068","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0069","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut"},{"issue":"9","key":"2023090515134187100_CIT0070","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ibd.21582","article-title":"Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study","volume":"17","author":"Vos","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2023090515134187100_CIT0071","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: A meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9701","key":"2023090515134187100_CIT0072","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"2023090515134187100_CIT0073","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: A nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"issue":"17","key":"2023090515134187100_CIT0074","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"8","key":"2023090515134187100_CIT0075","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2023090515134187100_CIT0076","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"2023090515134187100_CIT0077","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"2023090515134187100_CIT0078","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"2023090515134187100_CIT0079","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2023090515134187100_CIT0080","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","article-title":"Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"2023090515134187100_CIT0081","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/ajg.2014.298","article-title":"Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: A nationwide retrospective cohort","volume":"109","author":"Abbas","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2023090515134187100_CIT0082","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","article-title":"Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-\u03b1 inhibitor monotherapy and in combination with thiopurines: Analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"23","author":"McKenna","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"2023090515134187100_CIT0083","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","article-title":"TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: A systematic review","volume":"15","author":"Muller","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"8","key":"2023090515134187100_CIT0084","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: A Quebec Claims Database Study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2023090515134187100_CIT0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2023090515134187100_CIT0086","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.cgh.2019.04.047","article-title":"Sorting Through the risks and benefits of thiopurine therapy for inflammatory bowel diseases","volume":"17","author":"Singh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2023090515134187100_CIT0087","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2036.2004.01858.x","article-title":"Intestinal and extra-intestinal cancer in Crohn\u2019s disease: Follow-up of a population-based cohort in Copenhagen County, Denmark","volume":"19","author":"Jess","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"38","key":"2023090515134187100_CIT0088","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.3748\/wjg.v12.i38.6167","article-title":"Abnormalities of uterine cervix in women with inflammatory bowel disease","volume":"12","author":"Bhatia","year":"2006","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2023090515134187100_CIT0089","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal Pap smears in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"2023090515134187100_CIT0090","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2023090515134187100_CIT0091","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: A population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2023090515134187100_CIT0092","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/1097-0142(19861001)58:7<1569::AID-CNCR2820580731>3.0.CO;2-U","article-title":"Colorectal and extracolonic malignancy in ulcerative colitis","volume":"58","author":"Mir-Madjlessi","year":"1986","journal-title":"Cancer"},{"issue":"2","key":"2023090515134187100_CIT0093","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1023\/A:1008988215904","article-title":"Crohn\u2019s disease and cancer risk (Denmark)","volume":"11","author":"Mellemkjaer","year":"2000","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2023090515134187100_CIT0094","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2036.2008.03766.x","article-title":"Screening differences and risk of cervical cancer in inflammatory bowel disease","volume":"28","author":"Hutfless","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2023090515134187100_CIT0095","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.10.021","article-title":"Risk of cervical abnormalities in women with inflammatory bowel disease: A population-based nested case-control study","volume":"136","author":"Singh","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0096","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2023090515134187100_CIT0097","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1002\/ijc.29209","article-title":"Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: Population-based cohort study","volume":"136","author":"Dugu\u00e9","year":"2015","journal-title":"Int J Cancer"},{"issue":"7\u20138","key":"2023090515134187100_CIT0098","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/0959-8049(95)00133-4","article-title":"Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease","volume":"31A","author":"Tytgat","year":"1995","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023090515134187100_CIT0099","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.giec.2014.03.002","article-title":"Importance of nonpolypoid (flat and depressed) colorectal neoplasms in screening for CRC in patients with IBD","volume":"24","author":"Rutter","year":"2014","journal-title":"Gastrointest Endosc Clin North Am"},{"issue":"3","key":"2023090515134187100_CIT0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.giec.2014.03.009","article-title":"The unique pathology of nonpolypoid colorectal neoplasia in IBD","volume":"24","author":"Rubio","year":"2014","journal-title":"Gastrointest Endosc Clin North Am"},{"issue":"8889","key":"2023090515134187100_CIT0101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(94)90813-3","article-title":"Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis","volume":"343","author":"Bernstein","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"2023090515134187100_CIT0102","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/gut.35.10.1419","article-title":"Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis","volume":"35","author":"Connell","year":"1994","journal-title":"Gut"},{"issue":"8","key":"2023090515134187100_CIT0103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00054725-200608000-00001","article-title":"Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: A population-based study from Olmsted County, Minnesota","volume":"12","author":"Jess","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"2023090515134187100_CIT0104","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gut.52.8.1127","article-title":"Ten year follow up of ulcerative colitis patients with and without low grade dysplasia","volume":"52","author":"Lim","year":"2003","journal-title":"Gut"},{"issue":"12","key":"2023090515134187100_CIT0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3109\/00365529609036910","article-title":"Twenty years\u2019 colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation","volume":"31","author":"Lindberg","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"2023090515134187100_CIT0106","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/0016-5085(85)90653-5","article-title":"Surveillance for colonic carcinoma in ulcerative colitis","volume":"89","author":"Rosenstock","year":"1985","journal-title":"Gastroenterology"},{"issue":"10","key":"2023090515134187100_CIT0107","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/BF02253497","article-title":"Dysplasia in chronic ulcerative colitis: Implications for colonoscopic surveillance","volume":"35","author":"Taylor","year":"1992","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"2023090515134187100_CIT0108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2007.03241.x","article-title":"Meta-analysis: Cancer risk of low-grade dysplasia in chronic ulcerative colitis","volume":"25","author":"Thomas","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2023090515134187100_CIT0109","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.gastro.2003.08.023","article-title":"Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis","volume":"125","author":"Ullman","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090515134187100_CIT0110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0016-5085(92)90831-I","article-title":"Surveillance in the routine management of ulcerative colitis: The predictive value of low-grade dysplasia","volume":"103","author":"Woolrich","year":"1992","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0111","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2009.179804","article-title":"Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)","volume":"59","author":"Cairns","year":"2010","journal-title":"Gut"},{"issue":"2","key":"2023090515134187100_CIT0112","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"2023090515134187100_CIT0113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2023090515134187100_CIT0114","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.MIB.0000160811.76729.d5","article-title":"Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease","volume":"11","author":"Itzkowitz","year":"2005","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2023090515134187100_CIT0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1155\/2004\/983459","article-title":"Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening","volume":"18","author":"Leddin","year":"2004","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"2023090515134187100_CIT0116","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","article-title":"AGA Clinical Practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: Expert review","volume":"161","author":"Murthy","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"2023090515134187100_CIT0117","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal cancer in inflammatory bowel disease: Mechanisms and management","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"2023090515134187100_CIT0118","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: Ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2023090515134187100_CIT0119","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"12","key":"2023090515134187100_CIT0120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1055\/a-1031-7657","article-title":"Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019","volume":"51","author":"Bisschops","year":"2019","journal-title":"Endoscopy"},{"issue":"3","key":"2023090515134187100_CIT0121","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.gastro.2015.01.031","article-title":"SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease","volume":"148","author":"Laine","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"2023090515134187100_CIT0122","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1055\/a-1322-6574","article-title":"Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: A population-based cohort study","volume":"53","author":"Sch\u00f8nfeldt Troelsen","year":"2021","journal-title":"Endoscopy"},{"issue":"7","key":"2023090515134187100_CIT0123","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/ecco-jcc\/jjy044","article-title":"Incidence and classification of postcolonoscopy colorectal cancers in inflammatory bowel disease: A Dutch population-based cohort study","volume":"12","author":"Wintjens","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2023090515134187100_CIT0124","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/gutjnl-2018-316651","article-title":"Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: What are the differences from a non-IBD population","volume":"68","author":"Stj\u00e4rngrim","year":"2019","journal-title":"Gut"},{"issue":"4","key":"2023090515134187100_CIT0125","doi-asserted-by":"crossref","first-page":"e94208","DOI":"10.1371\/journal.pone.0094208","article-title":"5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: An updated meta-analysis","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"2023090515134187100_CIT0126","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/ajg.2012.198","article-title":"5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: A meta-analysis of non-referral populations","volume":"107","author":"Nguyen","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2023090515134187100_CIT0127","first-page":"2212","article-title":"Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: A meta-analysis","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"2023090515134187100_CIT0128","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"issue":"11","key":"2023090515134187100_CIT0129","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.cgh.2014.05.019","article-title":"Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: A meta-analysis","volume":"12","author":"Jess","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2023090515134187100_CIT0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/gut.2011.237412","article-title":"Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease","volume":"61","author":"van Schaik","year":"2012","journal-title":"Gut"},{"issue":"11","key":"2023090515134187100_CIT0131","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2023090515134187100_CIT0132","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(23)01998-4","article-title":"Epidemiology of small bowel cancers: A population-based study (Abstract)","author":"Singh","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"2023090515134187100_CIT0133","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: Primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2023090515134187100_CIT0134","first-page":"e111","article-title":"Practice Bulletin No. 168: Cervical cancer screening and prevention","volume":"128","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2023090515134187100_CIT0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: Preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2023090515134187100_CIT0136","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/LGT.0000000000000468","article-title":"Guidelines for cervical cancer screening in immunosuppressed women without HIV infection","volume":"23","author":"Moscicki","year":"2019","journal-title":"J Low Genit Tract Dis"},{"issue":"8","key":"2023090515134187100_CIT0137","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ibd.21567","article-title":"Screening for cervical and breast cancer among women with inflammatory bowel disease: A population-based study","volume":"17","author":"Singh","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"2023090515134187100_CIT0138","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: Inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"6","key":"2023090515134187100_CIT0139","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/MIB.0000000000000741","article-title":"Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy","volume":"22","author":"Poullenot","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2023090515134187100_CIT0140","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: A nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2023090515134187100_CIT0141","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"2023090515134187100_CIT0142","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"issue":"10","key":"2023090515134187100_CIT0143","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/ecco-jcc\/jjac061","article-title":"Comparative risk of incident cancer in patients with inflammatory bowel disease with prior non-digestive malignancy according to immunomodulator: A multicentre cohort study","volume":"16","author":"Poullenot","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"12","key":"2023090515134187100_CIT0144","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2023090515134187100_CIT0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/6\/Supplement_2\/S83\/51359323\/gwad006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/6\/Supplement_2\/S83\/51359323\/gwad006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T11:16:09Z","timestamp":1693912569000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/6\/Supplement_2\/S83\/7260529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":145,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,9,5]]},"published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwad006","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,9,1]]}}}